Abstract 54P
Background
Brain tumors are the most common tumors causing dysfunctions and the most fatal types of cancers. Patients with Parkinson’s disease (PD), the second most common neurodegenerative disorders, may be at high risk for brain tumors due to synucleins expression, chronic neuro-inflammation, levodopa therapy and radiations, but there is still controversy especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the risk of brain tumors in patients with PD in South Korea.
Methods
We analyzed 52,009 patients diagnosed with PD between 2010 and 2015, and the age- and sex-matched 260,045 individuals without PD (mean age: 71.3 years; 40.8% men), using the data from the Korean National Health Insurance Database. Patients previously diagnosed with cancer were excluded. The cohorts were followed up to 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the association between PD and brain cancer.
Results
Patients with PD had a higher brain cancer risk (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.05–2.85) in female patients with PD than in those without PD after adjustment for multiple covariates. There was no significant difference in brain tumor incidence between the two cohorts in men (HR, 1.02; 95% CI, 0.52-2.02).
Conclusions
This nationwide population-based cohort study revealed that patients with PD had higher risk of brain tumors than those without PD in Korea. Further studies are required to determine the underlying mechanisms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract